NASDAQ:APLS Stock Quote
Apellis Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for the treatment of serious diseases through its expertise in complement biology
The company works on advancing its proprietary drug candidates designed to modulate the immune system, with particular attention to rare and complex conditions that currently have limited treatment options. By harnessing advanced science and technology, Apellis aims to improve patient outcomes and address unmet medical needs in various therapeutic areas, including hematology and ophthalmology.
Frequently Asked Questions
Has Apellis Pharmaceuticals received any awards or recognitions?
Yes, Apellis Pharmaceuticals has received various recognitions for its innovative contributions to biopharma, particularly in the development of treatments for rare diseases. The company has been acknowledged for its growth and impact in the biotech ecosystem and has been included in industry-specific rankings and lists highlighting emerging and influential firms.
How can investors learn more about Apellis Pharmaceuticals?
Investors can learn more about Apellis Pharmaceuticals by visiting the company's official website, reviewing its investor relations section, and accessing financial reports, conference call transcripts, and information on product development. Additionally, staying informed through financial news outlets and stock analysis platforms can provide further insights.
How does Apellis Pharmaceuticals support patient communities?
Apellis Pharmaceuticals actively engages with patient communities to better understand their needs and challenges. The company provides educational resources, participates in awareness campaigns, and involves patients in clinical trials to ensure their voices are heard in the research and development process.
How has the COVID-19 pandemic affected Apellis Pharmaceuticals?
The COVID-19 pandemic impacted many biopharmaceutical companies, including Apellis Pharmaceuticals. The company experienced delays in clinical trials and operations initially; however, it took strategic steps to adapt to the challenges posed by the pandemic and continued to advance its product pipeline while ensuring the safety of its patients and staff.
Is Apellis Pharmaceuticals a publicly traded company?
Yes, Apellis Pharmaceuticals is publicly traded on the Nasdaq stock exchange under the ticker symbol APLS. The company's shares are available for purchase by individual and institutional investors.
What are analysts saying about APLS stock?
Analysts covering APLS stock provide various opinions based on the company's financial performance, product pipeline, and market potential. Many analysts analyze the potential success of pegcetacoplan and other therapies to determine price targets and recommendations, which can fluctuate based on ongoing clinical trial results and market conditions.
What are Apellis Pharmaceuticals' key products?
The key product of Apellis Pharmaceuticals is pegcetacoplan (brand name Syfovre), which has been approved for the treatment of geographic atrophy, an advanced form of age-related macular degeneration. The company is also developing other therapies that target various indications linked to the complement system.
What challenges does Apellis Pharmaceuticals face?
Like other biopharmaceutical companies, Apellis Pharmaceuticals faces challenges such as the need for substantial funding for research and development, navigating regulatory approvals for new drugs, and competition within the biotech industry, including similar therapies being developed by other companies.
What does Apellis Pharmaceuticals, Inc. do?
Apellis Pharmaceuticals, Inc. is a biotechnology company focused on the development of novel therapies for the treatment of rare diseases. The company leverages a deep understanding of the complement system, a part of the immune system, to create medicines aimed at improving the lives of patients suffering from conditions like geographic atrophy and other autoimmune disorders.
What is Apellis Pharmaceuticals' vision for the future?
Apellis Pharmaceuticals envisions a future where it can provide innovative treatments for patients with rare diseases caused by complement dysregulation. The company aims to advance its pipeline of therapies and expand its reach globally, ultimately improving patient outcomes and quality of life.
What is geographic atrophy?
Geographic atrophy is an advanced form of age-related macular degeneration (AMD) characterized by the progressive degeneration of retinal cells in the eye. It leads to vision loss and significantly impacts patients' quality of life. Treatment options have traditionally been limited, making novel therapies like those developed by Apellis particularly valuable.
What is the complement system?
The complement system is a part of the immune system that plays a critical role in enhancing the body's ability to fight infections, clear pathogens, and promote inflammation. However, dysregulation of the complement system can lead to various diseases, including autoimmune disorders, which is where Apellis Pharmaceuticals aims to intervene with its therapies.
What is the focus of Apellis Pharmaceuticals' research?
The focus of Apellis Pharmaceuticals' research is primarily on the complement system and its role in various diseases. By understanding how the complement system operates, the company aims to develop therapies that can mitigate its harmful effects in conditions such as geographic atrophy and other rare diseases.
What partnerships does Apellis Pharmaceuticals have?
Apellis Pharmaceuticals has established partnerships with various research institutions, healthcare providers, and other pharmaceutical companies to enhance its research capabilities and expedite the development of its therapies. These collaborations help leverage shared knowledge and resources in advancing innovative treatments.
What recent developments have occurred at Apellis Pharmaceuticals?
Apellis Pharmaceuticals has recently focused on expanding the clinical applications of pegcetacoplan and has pursued additional trials to explore its efficacy in other diseases. Furthermore, the company has engaged in partnerships and collaborations aimed at bolstering its research and development pipeline.
When was Apellis Pharmaceuticals founded?
Apellis Pharmaceuticals was founded in 2009. Since its inception, the company has worked on innovation in the biotech field, particularly focusing on therapies that target the complement system to treat rare diseases.
Where does Apellis Pharmaceuticals conduct its clinical trials?
Apellis Pharmaceuticals conducts its clinical trials in various locations, often collaborating with research institutions and hospitals across the United States and internationally. These trials are designed to assess the safety and efficacy of its drug candidates in diverse patient populations.
Where is Apellis Pharmaceuticals headquartered?
Apellis Pharmaceuticals is headquartered in Crestwood, Kentucky. This strategic location supports the company's R&D efforts and collaboration with various healthcare institutions and professionals in the biotechnology space.
Who are some of the key executives at Apellis Pharmaceuticals?
Some key executives at Apellis Pharmaceuticals include Cedric Francois, M.D., co-founder and CEO; and Dr. Aakash M. Jani, who serves in senior leadership roles focused on clinical development and regulatory affairs. The leadership team brings extensive experience in biotech, pharmaceuticals, and healthcare.
What is the current price of Apellis Pharmaceuticals, Inc. - Common Stock?
The current price of Apellis Pharmaceuticals, Inc. - Common Stock is 23.04
When was Apellis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Apellis Pharmaceuticals, Inc. - Common Stock was at 3:55 pm EDT on April 2nd, 2025
What is the market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock is 2.68B
How many shares of Apellis Pharmaceuticals, Inc. - Common Stock are outstanding?
Apellis Pharmaceuticals, Inc. - Common Stock has 116.46M shares outstanding.